8, 9 While the studys main goal (improving brain sugar use) wasnt achieved, secondary results were significant: Less brain shrinkage : People who got liraglutide lost 50% less brain tissue in areas important for memory and thinking
(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers
Whereas CD5 and IL-2 influence immune system functions and MMP2 is important in maintaining the extracellular matrix in skin, tendons and other connective tissue, and Tram1 increases protein production
Starting July 1st, Medicare is expanding access to GLP-1 weight-loss medications and your clients will have questions
Projects thematic foci ranging from nature-based solutions and disaster risk management to urban-rural planning, sustainable behavior, and resource efficiency
